Engineered CD9 antibodies and their use

Engineered CD9 antibodies and CARs provide a targeted and effective treatment for CD9+ cancers by specifically binding to CD9 protein, suppressing leukemia progression and improving survival rates while minimizing side effects.

WO2026037425A1 Publication Date: 2026-02-19THE CHINESE UNIVERSITY OF HONG KONG +1
4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/115177
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-16
Filing Date
2025-08-15
Publication Date
2026-02-19

AI Technical Summary

Technical Problem

Current methods for treating CD9-related diseases, particularly CD9+ cancers such as leukemia, are inadequate in terms of efficacy and specificity, necessitating the development of more effective therapeutic strategies.

Method used

Development of engineered CD9 antibodies, including single-chain variable fragments (scFvs) and humanized monoclonal antibodies, that specifically bind to human CD9 protein, combined with chimeric antigen receptors (CARs) to target and kill CD9-expressing cells.

Benefits of technology

The engineered antibodies effectively suppress leukemia progression, improve survival rates, and minimize platelet toxicity, offering a promising treatment for CD9+ cancers like B-cell acute lymphoblastic leukemia (B-ALL).

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure provides an antibody constructs that specifically bind CD9 with high affinity. These antibody constructs include a set of novel heavy chain and light chain complementarity determining regions (CDRs) sequences, optionally humanized variable regions, and engineered Fc region of the heavy chain constant region in order to eliminate undesirable platelet activation. The present invention also provides methods for diagnosing and treating conditions including cancer characterized by the aberrant expression of CD9 in the pertinent tissue and cells through the use of these anti-CD9 antibody constructs.
Need to check novelty before this filing date? Find Prior Art